Archives
-
Bortezomib and Proteasome Stress in Thymic Repair
2026-09-29
Bortezomib (PS-341) is more than a benchmark proteasome inhibitor: it can serve as a mechanistic probe for separating proteostasis stress, apoptosis, and adaptive thymic epithelial responses. This article connects multiple myeloma research with emerging thymic regeneration assays while defining the limits of applying bortezomib to the FOXN1 pathway.
-
Grazoprevir/Elbasvir Therapy for HCV: Evidence Review
2026-09-28
The reference paper positions grazoprevir/elbasvir as an interferon-free, two-target regimen that combines NS3/4A protease and NS5A inhibition for chronic HCV infection. Its main contribution is a clinically oriented synthesis of efficacy, safety, resistance, treatment duration, and use in difficult-to-treat populations rather than a new laboratory experiment.
-
Z-VAD-FMK Beyond Apoptosis: Mapping Pyroptosis
2026-09-28
Z-VAD-FMK is often used to test whether cell death depends on caspases, but inhibitor sensitivity alone does not identify apoptosis. This article applies a chicken gasdermin study to show how z vad fmk can help distinguish pathway involvement—and where its broad action limits interpretation.
-
Proteasome Inhibition as a Probe of Viral Immune Evasion
2026-09-27
Viral control of RIPK3 illustrates how targeted protein degradation can shape inflammation and infection. This article examines how Clasto-Lactacystin β-lactone can help translational researchers test proteasome dependence—while distinguishing global pharmacological inhibition from a virus’s selective degradation strategy.
-
Calpain Inhibitor II, ALLM: Interpreting Protease Effects
2026-09-26
Calpain Inhibitor II, ALLM, can probe cysteine-protease activity, but its multi-target profile makes experimental interpretation as important as dosing. This article connects ALLM assay design with new insight into calpain-2-dependent FAK stability in triple-negative breast cancer.
-
Phosphatase Inhibitor Cocktail 1 for Chordoma Signaling
2026-09-25
Protect labile phosphorylation signals while investigating how IDH1 inhibition reshapes chordoma biology. This workflow connects redox-metabolism findings to practical Western blot, immunoprecipitation, and phosphoproteomic experiments—without mistaking sample preservation for proof of mechanism.
-
Camostat Mesilate: Designing Causal Assays
2026-09-25
Camostat Mesilate can reveal how protease-linked processes influence epithelial sodium-channel function and fibrotic signaling—but a pathway-level effect is not proof of direct target engagement. This article shows how to build assays that separate those claims, using structure-guided proteomimetic research as a contrasting example of direct protein–protein interaction inhibition.
-
GI 254023X: ADAM10 Inhibitor Workflows
2026-09-24
GI 254023X offers a selective way to probe ADAM10-dependent shedding, with practical applications in Notch1 signaling and endothelial barrier models. This workflow-focused guide shows how to pair target-engagement assays with functional readouts while keeping the distinction between ADAM10 research and BACE neurobiology clear.
-
Bending Rigidity of the Red Blood Cell Membrane
2026-09-24
By separating the red blood cell cytoplasmic membrane from its spectrin network, Himbert and colleagues measured a low bending modulus of approximately 4–6 kBT using complementary scattering and simulation methods. The result helps explain why whole-cell and membrane measurements can differ, while emphasizing that membrane mechanics depend on the structure and length scale being studied.
-
MG-132 Workflows for Proteasome and Endothelial Assays
2026-09-23
Use MG-132 as a short-pulse probe to test whether proteasomal turnover contributes to a candidate protein’s regulation—not as a stand-alone readout of one ubiquitin ligase. This workflow translates the WWP2–DDX3X endothelial-injury study into practical controls for ubiquitination, apoptosis assay, and cell cycle arrest studies.
-
Hyaluronic Acid Sodium Salt for siRNA Nanoparticles
2026-09-23
Learn how to use Hyaluronic acid sodium salt as an extracellular matrix interface, nanoparticle coating, and assay variable in immune, infection, and tissue-modeling workflows. The guide translates a recent TDRD9-siRNA study into practical formulation, controls, troubleshooting, and validation steps.
-
Aclacinomycin A for rDNA Damage Workflows
2026-09-22
Use Aclacinomycin A as a tunable topological-stress reagent to connect persistent ribosomal DNA lesions with PML-nucleolar associations, apoptosis, and proteasome-related responses. This workflow combines viability benchmarking with time-resolved imaging, helping distinguish early DNA-damage signaling from late, nonspecific cell death.
-
IBDV VP3 Disrupts IRF7 Signaling to Aid Replication
2026-09-22
A 2025 study identifies IBDV VP3 as a viral antagonist of the chicken IRF7–IFN-β antiviral axis. By combining infection comparisons, IRF7 gain- and loss-of-function experiments, proteasome-pathway tests, and protein-interaction analyses, the authors show how very virulent IBDV promotes IRF7 loss to support replication.
-
HNRNPU K181 Lactylation Rewires Serine Metabolism
2026-09-21
The reference study identifies HNRNPU K181 lactylation as a non-histone, lactate-responsive mechanism that stabilizes HNRNPU, preserves PHGDH transcripts, and promotes serine metabolic reprogramming in cervical cancer. Its combination of transcriptomic, proteomic, molecular, metabolic, and in vivo evidence provides a framework for connecting tumor lactate accumulation with post-transcriptional gene regulation and cancer growth.
-
CerS6 Links Stress to Hepatocyte Mitochondrial Injury
2026-09-21
Liu et al. identify CerS6-derived mitochondrial C16:0 ceramide as a mechanistic link between corticosterone-associated stress and hepatocyte mitochondrial injury. By combining restraint stress, a corticosterone cell model, LC–MS/MS lipid profiling, pathway inhibition, and CerS6 knockdown, the study connects AMPK/p38 MAPK signaling with ceramide-mediated cytochrome c release.